Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cambium BioASX:CMB 24 Price-to-Tangible-Book is 76.67 as of Sep. 15, 2026. GuruFocus rates ASX:CMB with a GF Score™ of 24/100. The stock has 4 warning signs investors should review. Among 1,135 Biotechnology companies, Cambium Bio ranks worse than 88105.64% on this metric.
As of today (2026-09-15), Cambium Bio's share price is A$0.46. Cambium Bio's Tangible Book per Share of Dec. 2025 for the quarter that ended in Dec. 2025 was A$0.01. Hence, Cambium Bio's Price to Tangible Book Ratio of today is 76.67.
The historical rank and industry rank for Cambium Bio's Price-to-Tangible-Book or its related term are showing as below:
During the past 13 years, Cambium Bio's highest Price to Tangible Book Ratio was 78.33. The lowest was 2.97. And the median was 8.81.
ASX:CMB's Price-to-Tangible-Book is not ranked *
in the Biotechnology industry.
Industry Median: 3.31 * Ranked among companies with meaningful Price-to-Tangible-Book only.
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Cambium Bio Price-to-Tangible-Book Related Terms
Cambium Bio Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for Cambium Bio's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CMB vs VRTX, REGN, MRNA: Price-to-Tangible-Book Comparison
For the Biotechnology subindustry, Cambium Bio's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cambium Bio Price-to-Tangible-Book vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cambium Bio's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Cambium Bio's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Cambium Bio (ASX:CMB) has a Price-to-Tangible-Book of 76.67 as of Sep. 15, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Cambium Bio and its competitors. According to the industry distribution chart, Cambium Bio ranks #999999 out of 1135 companies in the Biotechnology industry.
Is Cambium Bio's Price-to-Tangible-Book too high?
Cambium Bio's current Price-to-Tangible-Book is 76.67. The Biotechnology industry median Price-to-Tangible-Book is 3.31. Cambium Bio's value of 76.67 is 2216.3% above this industry median. Based on the distribution chart, Cambium Bio ranks #999999 out of 1135 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cambium Bio has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Cambium Bio's Price-to-Tangible-Book compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cambium Bio ranks #999999 out of 1135 companies for Price-to-Tangible-Book. This places Cambium Bio in the lower half of its industry. The industry median Price-to-Tangible-Book is 3.31. Cambium Bio's value of 76.67 is 2216.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Biotechnology company?
The median Price-to-Tangible-Book among Biotechnology companies is 3.31, based on 1,135 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cambium Bio's current Price-to-Tangible-Book of 76.67 is 2216.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Cambium Bio and its competitors. For the Biotechnology industry, the median Price-to-Tangible-Book is 3.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cambium Bio's current Price-to-Tangible-Book is 76.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cambium Bio stock overvalued right now?
Cambium Bio (ASX:CMB) has a current Price-to-Tangible-Book of 76.67. The current Price-to-Tangible-Book is 76.67 and 2216.3% above the Biotechnology industry median of 3.31. Cambium Bio's overall GF Score™ is 24/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Cambium Bio (ASX:CMB), the current Price-to-Tangible-Book is 76.67 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cambium Bio Ltd is a clinical-stage regenerative medicine company in Australia. It focuses on the development of biologics for ophthalmology and tissue repair applications. Its technology platform is based on human platelet lysate, which is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The company's product candidate, Elate Ocular, is being developed to address unmet medical needs in the treatment of dry eye disease. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications.
24GF Score
Get the complete analysis for ASX:CMB
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CMB has been successfully added to your 
